维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

已收盘 12-05 16:09:08

51.700

-0.800

-1.52%

最高52.500	最低51.400	成交量38.62万
今开52.500	昨收52.500	日振幅2.10%
总市值102.88亿	流通市值79.10亿	总股本1.99亿
成交额2,002万	换手率0.25%	流通股本1.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":51.7,"timestamp":1764922148009,"preClose":52.5,"halted":0,"volume":386231,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"已收盘","change":-0.8,"latestTime":"12-05 16:09:08","open":52.5,"high":52.5,"low":51.4,"amount":20016412,"amplitude":0.020952,"askPrice":51.7,"askSize":18500,"bidPrice":51.4,"bidSize":6500,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":52.5,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":0.651034,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887/tweets","defaultTab":"tweets","newsList":[{"id":"2588838525","title":"每日卖空追踪 | 维立志博-B 12月04日卖空量成交4.02万股，卖空比例为7.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588838525","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588838525?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:30","pubTimestamp":1764837041,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间12月04日，跌0.94%，卖空量成交4.02万股，较上一交易日减少80.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163647978f8911&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163647978f8911&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09887","BK1161"],"gpt_icon":0},{"id":"2588039756","title":"已达成超10亿美元合作，维立志博自免1类新药在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2588039756","media":"药渡","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588039756?lang=zh_cn&edition=full","pubTime":"2025-12-02 07:32","pubTimestamp":1764631937,"startTime":"0","endTime":"0","summary":"近日，中国国家药监局药品审评中心官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。值得一提的是，今年10月，维立志博宣布与Dianthus Therapeutics达成独家全球合作伙伴关系，共同推进LBL-047。维立志博将授予Dianthus在大中华区以外独家研发、生产及商业化LBL-047的权益，获得最高3800万美元的首付款及近期里程碑付款，其中包括2000万美元首付款、2025年第四季度支付的500万美元，以及最高1300万美元的潜在近期里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202091720a4c6c9a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202091720a4c6c9a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09887"],"gpt_icon":0},{"id":"2588382740","title":"维立志博-B(09887)：LBL-047取得NMPA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588382740","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588382740?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:32","pubTimestamp":1764577967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，于2025年11月25日，其自主研发候选药物LBL-047的新药临床试验申请已获中国国家药品监督管理局批准。目前全球范围内尚无同时靶向浆细胞样树突状细胞及B细胞的药物获批临床试验。LBL-047凭借此独特作用机制，具备同类第一及同类最优的潜力。其将评估LBL-047的安全性、耐受性及其在SLE患者中的初步临床有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","09887","HK0000252152.HKD","HK0000500386.USD","IND"],"gpt_icon":0},{"id":"2588471777","title":"每日卖空追踪 | 维立志博-B 12月01日卖空量成交3.08万股，卖空比例为6.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588471777","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588471777?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:30","pubTimestamp":1764577840,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间12月01日，跌0.94%，卖空量成交3.08万股，较上一交易日减少24.69%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163628a71c7317&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163628a71c7317&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"1196990754","title":"南京维立志博(9887)临时股东大会将审议H股奖励计划等议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1196990754","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196990754?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:17","pubTimestamp":1764339460,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技股份有限公司(股份代号：9887)将于2025年12月17日上午十时在中国南京市嘉陵江东街18号3幢8层召开临时股东大会，大会将以投票方式审议特别决议案，包括采纳H股奖励计划、授权董事会及/或代表办理相关事宜，以及就最多不超过已发行股份5%的新股配发申请上市。\n此外，还将表决服务供应商分项限额、取消监事会及修订公司章程等事项。更多详情可查阅香港联交所网站（www.hkexnews.hk）及公司网站（www.leadsbiolabs.com）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2586214365","title":"速递丨已达成超10亿美元合作，维立志博自免1类新药在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2586214365","media":"医药观澜","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586214365?lang=zh_cn&edition=full","pubTime":"2025-11-27 11:41","pubTimestamp":1764214913,"startTime":"0","endTime":"0","summary":"中国国家药监局药品审评中心官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。值得一提的是，今年10月，维立志博宣布与Dianthus Therapeutics达成独家全球合作伙伴关系，共同推进LBL-047。维立志博将授予Dianthus在大中华区以外独家研发、生产及商业化LBL-047的权益，获得最高3800万美元的首付款及近期里程碑付款，其中包括2000万美元首付款、2025年第四季度支付的500万美元，以及最高1300万美元的潜在近期里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD"],"gpt_icon":0},{"id":"2586252169","title":"每日卖空追踪 | 维立志博-B 11月26日卖空量成交4900股，卖空比例为1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586252169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586252169?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:30","pubTimestamp":1764145838,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月26日，涨3.2%，卖空量成交4900股，较上一交易日减少93.61%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163622a71285c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163622a71285c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","09887","BK1161"],"gpt_icon":0},{"id":"2586712044","title":"维立志博-B(09887)建议采纳H股奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2586712044","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586712044?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:48","pubTimestamp":1764082115,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2025年11月25日审议批准建议采纳H股奖励计划。H股奖励计划旨在：促进实现公司长远可持续发展及业绩目标;把受让人的利益与股东、投资者及公司的利益紧密联系起来，从而增强公司凝聚力，促进公司实现最大价值;及完善公司激励机制，以吸引、激励及留聘对公司持续经营、发展及长远增长贡献良多的集团董事、高级管理层及雇员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","09887","HK0000252160.HKD","BK1161","HK0000252152.HKD"],"gpt_icon":0},{"id":"2586499055","title":"2025中国TCE赛道全景：百余管线竞逐，谁将领跑免疫治疗新纪元？","url":"https://stock-news.laohu8.com/highlight/detail?id=2586499055","media":"ITBEAR科技资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586499055?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:06","pubTimestamp":1763978796,"startTime":"0","endTime":"0","summary":"与ADC依赖细胞毒素杀伤肿瘤细胞不同，TCE通过激活免疫系统实现治疗，对靶点表达量的要求较低，但对肿瘤特异性要求更高。在血液瘤领域，TCE已取得显著成果。截至2025年7月，全球已有9款TCE双抗获批上市，覆盖多发性骨髓瘤、弥漫大B淋巴瘤等多个适应症，市场规模超百亿美元。其CD19/BCMA/CD3三抗LBL-051通过NewCo模式与Aditum Bio合作，交易总额达6.14亿美元，创下国内临床前TCE管线授权纪录。平台型药企在TCE领域的优势日益凸显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124181626a70e196f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124181626a70e196f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1587","BK1574","09887","BK1161","02162"],"gpt_icon":0},{"id":"2586349287","title":"每日卖空追踪 | 维立志博-B 11月24日卖空量成交2.5万股，卖空比例为2.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586349287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586349287?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:30","pubTimestamp":1763973039,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月24日，跌0.49%，卖空量成交2.5万股，较上一交易日减少77.88%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124163606a70de1d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124163606a70de1d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","BK1161","09887","HK0000500386.USD","HK0000252160.HKD"],"gpt_icon":0},{"id":"2585863834","title":"创新药双周报：4-1BB：复盘历史失败原因 维立志博做对了什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2585863834","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585863834?lang=zh_cn&edition=full","pubTime":"2025-11-23 00:00","pubTimestamp":1763827200,"startTime":"0","endTime":"0","summary":"目前有两款在研4-1BB双抗从设计上解决肝毒性，同时展现了惊艳的疗效，有望改写历史。MET-233i通过创新机制在Phase 1研究中单药即实现8.4%的安慰剂校正体重下降，且其约19天的半衰期为开发月度给药的固定剂量复方制剂奠定基础。这是全球首个 ADC 药物在食管癌治疗中取得 PFS/OS 双阳性结果的 III 期临床研究。创新药双周建议关注组合：康方生物、三生制药、映恩生物、信达生物、先声药业、歌礼制药、维立志博。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251123172134a4b4c2d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251123172134a4b4c2d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348767384.USD","LU0634319403.HKD","LU2488822045.USD","LU2778985437.USD","LU0417516571.SGD","BK1161","LU1720050803.USD","LU0561508036.HKD","IE00BPRC5H50.USD","BK1574","09926","LU0348766576.USD","IE00B543WZ88.USD","LU2476274720.SGD","09887","HK0000252160.HKD","LU0348827113.USD","LU0540923850.HKD","LU2476274308.USD","IE00B5MMRT66.SGD","HK0000252152.HKD","06978","LU0348783233.USD","LU1961090484.USD","LU1794554557.SGD","LU0417516738.SGD","LU0348825331.USD","LU2399975544.HKD","HK0000500386.USD","LU0348735423.USD","LU0348784397.USD","LU0417516902.SGD"],"gpt_icon":0},{"id":"2585682155","title":"每日卖空追踪 | 维立志博-B 11月20日卖空量成交1.36万股，卖空比例为4.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585682155","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585682155?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:30","pubTimestamp":1763627439,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月20日，跌0.47%，卖空量成交1.36万股，较上一交易日减少68%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120163804a706491d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120163804a706491d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2585651155","title":"创新药港股AB面","url":"https://stock-news.laohu8.com/highlight/detail?id=2585651155","media":"深蓝观","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585651155?lang=zh_cn&edition=full","pubTime":"2025-11-20 07:14","pubTimestamp":1763594040,"startTime":"0","endTime":"0","summary":"在2025年1月份的JP摩根医疗健康大会上，正好是中国创新药资产被全世界看见的时刻，会场上放眼望去，目之所及都是中国面孔。不过短短几个月，二级市场IPO开闸，3月份国际资金回流中国股市，港股IPO张灯结彩，2月份，一些即将上市的biotech又面临基石投资难求的困境，2个月后，基石又被疯抢。-02-繁华下的异动前几年被国内商业化、外资撤出等因素压下来的创新药的繁荣，2025年下半年，在港股打开一扇门后，被压抑的火苗，熊熊燃烧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120075224950f62e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120075224950f62e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09606","09887","06978","BK1161"],"gpt_icon":0},{"id":"2584978543","title":"维立志博-B11月19日主力净流出61.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2584978543","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584978543?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:16","pubTimestamp":1763540164,"startTime":"0","endTime":"0","summary":"11月19日, 维立志博-B股价跌2.29%，报收53.35元，成交金额2827.6万元，换手率0.35%，振幅6.04%，量比1.08。维立志博-B今日主力资金净流出61.5万元，上一交易日主力净流入50.1万元。该股近5个交易日下跌7.06%，主力资金累计净流出109.6万元；近20日主力资金累计净流入634.2万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119162300a4ac4951&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119162300a4ac4951&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2584288932","title":"每日卖空追踪 | 维立志博-B 11月18日卖空量成交1.43万股，卖空比例为2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584288932","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584288932?lang=zh_cn&edition=full","pubTime":"2025-11-18 16:30","pubTimestamp":1763454639,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月18日，跌5.86%，卖空量成交1.43万股，较上一交易日减少72.97%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118163652950bc636&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118163652950bc636&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2584462576","title":"每日卖空追踪 | 维立志博-B 11月17日卖空量成交2.87万股，卖空比例为7.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584462576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584462576?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:30","pubTimestamp":1763368238,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月17日，跌1.69%，卖空量成交2.87万股，较上一交易日减少0.35%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117163615a4a72f33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117163615a4a72f33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2583689715","title":"每日卖空追踪 | 维立志博-B 11月14日卖空量成交1.9万股，卖空比例为3.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583689715","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583689715?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:30","pubTimestamp":1763109041,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月14日，跌0.84%，卖空量成交1.9万股，较上一交易日增加100%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114164202a4a11cb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114164202a4a11cb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2583689796","title":"维立志博-B11月14日主力净流出147.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2583689796","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583689796?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:16","pubTimestamp":1763108161,"startTime":"0","endTime":"0","summary":"11月14日, 维立志博-B股价跌0.84%，报收59.00元，成交金额3174.6万元，换手率0.35%，振幅6.22%，量比1.18。维立志博-B今日主力资金净流出147.5万元，上一交易日主力净流入49.2万元。该股近5个交易日上涨0.94%，主力资金累计净流入632.4万元；近20日主力资金累计净流入613.8万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511141624099768f5fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511141624099768f5fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2582430802","title":"解析！16家江苏创新药公司Q3获融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2582430802","media":"创鉴汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582430802?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:13","pubTimestamp":1762938791,"startTime":"0","endTime":"0","summary":"2025年第三季度，江苏创新药生态继续展现韧性与分层活力。据统计，Q3至少有16家江苏创新药公司获融资，已披露金额合计超25亿元。本季度亿元及以上融资事件共5起，在总额中占比较高。7家获融资公司布局抗肿瘤相关项目，且多为实体瘤与血液瘤并行布局；同时女性健康（4起）、中枢神经（3起）、代谢疾病（3起）、皮肤科（3起）等领域融资活跃。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112192029a6f45ac6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112192029a6f45ac6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1110","02116","09887"],"gpt_icon":0},{"id":"2582109113","title":"【券商聚焦】信达证券维持维立志博(09887)“买入”评级 指公司资金充裕充分保障多条管线开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2582109113","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582109113?lang=zh_cn&edition=full","pubTime":"2025-11-12 10:48","pubTimestamp":1762915704,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达证券发研报指，维立志博 2025年11月9日研发日更新多个产品研发进展。大样本临床数据表明：LBL-024彻底解决4-1B乙肝毒性问题。LBL-024在NSCLC领域崭露头角，具备成为二代IO基石药物的潜力。资金充裕充分保障多条管线开发。截止到2025H1公司现金及现金等价物4.22亿元，除此之外，2025年7月公司首次公开发行募资所得净额13.63亿港币，充裕的资金储备为公司多条研发管线的快速推进提供了坚强保障。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969485","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601059","09887"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":0.0174},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.2021},{"period":"6month","weight":0.5},{"period":"ytd","weight":0.5}],"compareEarnings":[{"period":"1week","weight":-0.0004},{"period":"1month","weight":-0.0006},{"period":"3month","weight":0.0204},{"period":"6month","weight":0.0901},{"period":"1year","weight":0.3137},{"period":"ytd","weight":0.2929}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}